# T3 Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/t3-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Allschwil, Switzerland
- Website: www.t3pharma.com
- Total disclosed funding: $12M
- Latest round: Series A (Sep 26, 2019)
- Investors on record: 2

## About

Based in Switzerland, T3 Pharmaceuticals AG is a biopharmaceutical company focused on developing innovative therapies aimed at addressing unmet medical needs in oncology and immuno-oncology.T3 Pharmaceuticals AG, founded in 2015 and headquartered in Allschwil, Switzerland, specializes in creating advanced biopharmaceutical products. The company was co-founded by Christoph Kasper, Marlise Amstutz, and Simon Ittig, with Simon Ittig currently serving as CEO. T3 Pharma has successfully completed three deals, with the latest funding round occurring on July 22, 2020, raising CHF 25 million from investors including Boehringer Ingelheim Venture, Reference Capital Management, and Wille Finance. The total amount raised by the company stands at CHF 450 million.T3 Pharmaceuticals AG specializes in developing innovative biopharmaceutical products that address significant unmet medical needs in oncology and immuno-oncology. Their primary offerings include advanced therapies designed to harness the immune system's power in combatting various cancers, enhancing existing treatment protocols and providing personalized medicine solutions. Their client base consists of healthcare providers, research institutions, and pharmaceutical partners in North America and Europe, ultimately benefiting oncology patients with tailored therapies aimed at improving outcomes and quality of life.T3 Pharmaceuticals AG generates revenue through strategic partnerships and collaborations in the biopharmaceutical sector. Their business model includes B2B agreements with healthcare institutions and pharmaceutical companies, enabling the distribution and administration of their proprietary therapies. Revenue streams are structured around milestone payments, licensing agreements, and potential profit-sharing from product sales. While specific pricing plans for their therapies are not publicly disclosed, their revenue framework is built on the successful advancement of products through clinical trials and regulatory approvals, leading to commercialization, with flagship products central to their strategy.T3 Pharmaceuticals AG aims to leverage the CHF 25 million raised in July 2020 to further its development of innovative therapies and expand its market presence. The company is focusing on the launch of new products designed to meet the evolving needs of oncology patients. Additionally, T3 Pharma plans to expand its operations into new geographic regions, targeting markets in Asia and North America by 2023. The recent funding will support the ongoing clinical trials and regulatory processes necessary for product commercialization.

## Funding rounds

- Series A, Sep 26, 2019, $12M — Reference Capital Management, Boehringer Ingelheim Venture

## Investors

- Reference Capital Management (https://capitalatlas.ai/funds/reference-capital-management) — Series A
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series A